• ISSCR Applauds Australia’s Move to Regulate Autologous Human Cell and Tissue Products

  • 26 April, 2018

    • The ISSCR appreciates the new framework proposed by Australia’s Therapeutic Goods Administration (TGA) for the regulation of human cell and tissue products that use a person’s own cells (‘autologous use’).
    Full story

  • Media Registration Open for ISSCR 2018 20-23 June, Melbourne, AUS

  • 21 March, 2018

    • Credentialed reporters can register and attend the 2018 annual meeting in Melbourne, Australia. They will have access to the many stem cell researchers and clinicians from around the world who will be discussing recent findings and progress that is driving development of stem cell treatments and cures for disease.
    Full story

  • ISSCR Announces Two New Science Communications & Education Managers

  • 4 January, 2018

    • The ISSCR has selected Christopher Barry, PhD, and Julie Perlin, PhD, to be Science Communications & Education Managers, beginning 3 January, 2018.
    Full story

  • ISSCR Remembers Hiromitsu “Hiro” Ogawa

  • 4 January, 2018

    • The ISSCR is saddened by the passing of Hiromitsu “Hiro” Ogawa, a generous and thoughtful man who was a great supporter of stem cell science and the ISSCR.
    Full story

  • ISSCR Applauds the FDA Announcement of New Guidelines for Cellular Therapies and Cell-based Tissue Products

  • 17 November, 2017

    • The ISSCR commends the U.S. Food and Drug Administration (FDA) for reaffirming its regulatory authority over stem cell biologics and clarifying the criteria that determine which cell-based products fall under its oversight. These guidance documents will provide greater transparency for patients, medical professionals, and law enforcement authorities, about the legal status of stem cell treatments in the U.S.
    Full story

  • ISSCR Applauds California Bill to Assist Stem Cell Patients

  • 4 October, 2017

    • A measure signed into law 3 October in the state of California, U.S., requires clinics to inform patients if they are using stem cell interventions that have not been approved by the Food and Drug Administration (FDA). ISSCR president Hans Clevers expresses support for the measure.
    Full story

  • ISSCR Responds to FDA Announcement of Enforcement Direction for Stem Cell Treatments

  • 28 August, 2017

    • The ISSCR commends the U.S. Food and Drug Administration (FDA) for its policy direction and enforcement efforts, to provide “bright lines and appropriate oversight” for regulating stem cell treatments and regenerative medicine.
    Full story

  • ISSCR Comments on U.S. Study to Correct Disease Genes in Human Embryos

  • 2 August, 2017

    • A study on the first use of CRISPR technology in the U.S. to correct a disease-causing genetic defect in early stage human embryos.
    Full story

  • Letter to Texas House of Representatives, U.S., Opposing Legislation It Says Would Put Patients at Risk

  • 6 May, 2017

    • 5/6/2017 4:00:00 AM

    The ISSCR wrote to members of the Texas House of Representatives, U.S., to oppose House Bill 661, House Bill 810, and House Bill 3236, which would allow investigational agents to be sold to patients without first providing rigorous evidence of safety and efficacy. The ISSCR believes the legislation would put patients at serious risk of harm from unproven treatments.
    Full story

  • ISSCR Expresses Concern over FY2018 Budget Proposal in U.S.

  • 17 March, 2017

    • The FY2018 Discretionary Budget Plan put forward by the U.S. Administration includes dramatic cuts in funding for science and research programs that would threaten biomedical research and its translation into new therapies for millions of people worldwide.
    Full story

  • The ISSCR Opposes U.S. Administration Executive Order on Immigration

  • 30 January, 2017

    • 1/30/2017 6:00:00 AM

    The ISSCR issued a statement opposing a U.S. executive order on immigration.
    Full story

  • The ISSCR Announces 2017 Award Recipients: McEwen Award for Innovation, ISSCR Dr. Susan Lim Outstanding Young Investigator Award, ISSCR Tobias Award Lecture, and ISSCR Public Service Award

  • 23 January, 2017

    • 1/23/2017 6:00:00 AM

    The ISSCR awards recognize outstanding scientists in the field of stem cell research and regenerative medicine. Award recipients are selected by their peers, and receive the honor at the ISSCR annual meeting, where they are invited to present their science.
    Full story

  • ISSCR Comments on 21st Century Cures Act in U.S.

  • 9 December, 2016

    • The ISSCR supports the increase in biomedical research funding in the 21st Century Cures Act in the U.S. It also underscores concern that the bill's streamlined process for FDA review and approval of regenerative therapies include a rigorous review of scientific and clinical evidence to ensure safety and efficacy.
    Full story

  • ISSCR Comments to Australian Therapeutic Goods Administration on Regulation of Autologous Cell and Tissue Products

  • 1 November, 2016

    • In comments to the Australian Therapeutic Goods Administration (TGA), the ISSCR supported regulation of autologous products that involve more than minimal manipulation of a patient’s cells and place strict limitations on the direct advertisement of cell-based therapies. The comments were in response to the TGA's call for input from interested parties about the regulation of autologous cell and tissue products.
    Full story

  • European Society of Gene and Cell Therapy & ISSCR to Present Latest in Stem Cell Research, Gene Editing and Gene Therapy 18-21 Oct., Florence IT - 30 Sept., 2016

  • 30 September, 2016

    • The European Society of Gene and Cell Therapy (ESGCT) & ISSCR host an International Symposium to Present the Latest in Stem Cell Research, Gene Editing and Gene Therapy. Latest news and developments in research will be part of the scientific programming.
    Full story

  • ISSCR Opposes the REGROW Act

  • 15 September, 2016

    • The ISSCR opposes the REGROW Act, which would allow certain cell and tissue-based therapeutics to be marketed without first providing rigorous evidence of safety and efficacy. If passed, this legislation could negatively impact the development of stem cell therapies, the integrity of the emerging regenerative medicine market, and the health and safety of people using stem cell products approved under this Act.
    Full story

  • ISSCR Comments Before FDA Panel on Draft Guidances Relating to the Regulation of Human Cells, Tissues, or Cellular or Tissue-Based Products

  • 13 September, 2016

    • The ISSCR today underscored the need for careful oversight and regulation of stem cell research at every stage in the process of developing therapeutic products for patient use.
    Full story

  • ISSCR Comments Regarding Proposed Changes to the U.S. National Institutes of Health Guidelines on Human Stem Cell Research

  • 7 September, 2016

    • The ISSCR supports the continued assessment of the U.S. National Institutes of Health (NIH) Guidelines for Human Stem Cell Research. We applaud the proposed end to the current moratorium on U.S. federal funding of human-animal chimera research involving the introduction of human pluripotent cells into early stage animal embryos.
    Full story

  • ISSCR Congratulates George Q. Daley on Being Named Dean of Harvard Medical School

  • 10 August, 2016

    • ISSCR Congratulates George Q. Daley, ISSCR past president, for being named dean of Harvard Medical School. August, 2016.
    Full story
    View All ISSCR News